Blisters, peeling, or sores in the mouth or eyes with a rash. Enfortumab vedotin carries a boxed warning for Stevens-Johnson syndrome and toxic epidermal necrolysis, mostly in the first cycle.
Sudden severe abdominal pain, a hard or very tender abdomen, or abdominal pain with vomiting and fever. Boxed warning for gastrointestinal perforation on bevacizumab.
Fainting, near-fainting, or an irregular or racing heartbeat; several kinase inhibitors prolong the QT interval and the labels require ECG and electrolyte monitoring.
Am I a candidate for Mirvetuximab soravtansine, Relacorilant, Pembrolizumab, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Prevention and risk
For my situation (prevention and risk), which of the standard options do you recommend and why?
Why: Guideline options include: Germline testing for all patients; risk-reducing salpingo-oophorectomy for BRCA carriers (age 35-45); opportunistic salpingectomy at pelvic surgery for average-risk women; oral contraceptives reduce risk. No population screening (UKCTOCS negative).
How do the results of UKCTOCS apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.
Newly diagnosed stage I-II
For my situation (newly diagnosed stage i-ii), which of the standard options do you recommend and why?
Why: Guideline options include: Complete surgical staging; adjuvant carboplatin-paclitaxel for high-grade or stage IC-II disease; observation for low-risk stage IA-IB grade 1-2.
Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Newly diagnosed stage III-IV: surgery and chemotherapy
For my situation (newly diagnosed stage iii-iv: surgery and chemotherapy), which of the standard options do you recommend and why?
Why: Guideline options include: Primary debulking if complete resection is feasible, else 3 cycles neoadjuvant carboplatin-paclitaxel then interval debulking (with HIPEC in stage III, OVHIPEC-1) and 3 more cycles; add bevacizumab for high-risk or residual disease.
Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, Bevacizumab, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of OVHIPEC-1 and GOG-0218 & ICON7 (bevacizumab) apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.
First-line maintenance, BRCA-mutated
For my situation (first-line maintenance, brca-mutated), which of the standard options do you recommend and why?
Why: Guideline options include: Olaparib 2 years (SOLO-1) or olaparib + bevacizumab (PAOLA-1) or niraparib 3 years (PRIMA).
Am I a candidate for Olaparib, Niraparib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of SOLO-1 and PAOLA-1 / ENGOT-ov25 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.
For my situation (first-line maintenance, hrd-positive brca-wild-type), which of the standard options do you recommend and why?
Why: Guideline options include: Olaparib + bevacizumab (PAOLA-1, OS benefit) or niraparib (PRIMA, PFS only).
Am I a candidate for Olaparib, Bevacizumab, Niraparib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of PAOLA-1 / ENGOT-ov25 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.
First-line maintenance, HRD-negative
For my situation (first-line maintenance, hrd-negative), which of the standard options do you recommend and why?
Why: Guideline options include: Bevacizumab continuation if started; niraparib is an option with small PFS benefit and no OS benefit (PRIMA); observation is reasonable.
Am I a candidate for Bevacizumab, Niraparib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of PRIMA / ENGOT-OV26 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.
Platinum-sensitive relapse (interval >6 months)
For my situation (platinum-sensitive relapse (interval >6 months)), which of the standard options do you recommend and why?
Why: Guideline options include: Secondary cytoreduction if AGO-score positive (DESKTOP III); platinum doublet (carboplatin with PLD, paclitaxel, or gemcitabine) ± bevacizumab; PARP maintenance if PARP-naive and BRCA/HRD-positive.
Am I a candidate for Carboplatin, Pegylated liposomal doxorubicin, Bevacizumab or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of DESKTOP III / ENGOT-ov20 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.
Platinum-resistant relapse, FRα-high
For my situation (platinum-resistant relapse, frα-high), which of the standard options do you recommend and why?
Why: Guideline options include: Mirvetuximab soravtansine (MIRASOL, OS benefit) with ophthalmic prophylaxis.
Am I a candidate for Mirvetuximab soravtansine, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of MIRASOL / GOG-3045 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.
Platinum-resistant relapse, PD-L1 CPS ≥1
For my situation (platinum-resistant relapse, pd-l1 cps ≥1), which of the standard options do you recommend and why?
Am I a candidate for Pembrolizumab, Paclitaxel / nab-paclitaxel, Bevacizumab, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of KEYNOTE-B96 / ENGOT-ov65 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.
Platinum-resistant relapse, other
For my situation (platinum-resistant relapse, other), which of the standard options do you recommend and why?
Why: Guideline options include: Relacorilant + nab-paclitaxel (ROSELLA, approved 2026); single-agent weekly paclitaxel, PLD, or topotecan ± bevacizumab (AURELIA); clinical trials of FRα and CDH6 ADCs.
Am I a candidate for Relacorilant, Pegylated liposomal doxorubicin, Bevacizumab or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of ROSELLA / GOG-3073 and AURELIA apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.
Low-grade serous carcinoma
For my situation (low-grade serous carcinoma), which of the standard options do you recommend and why?
Why: Guideline options include: Surgery; endocrine maintenance (letrozole) after chemotherapy or instead of it; at recurrence, avutometinib + defactinib if KRAS-mutated (2025), trametinib, or endocrine therapy.
Am I a candidate for Letrozole (and other aromatase inhibitors), Avutometinib + defactinib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of RAMP 201 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.
Rare histologies
For my situation (rare histologies), which of the standard options do you recommend and why?
Why: Guideline options include: Clear-cell: platinum-based therapy, trials of immunotherapy and ARID1A-directed agents; mucinous: consider GI regimens and HER2 testing; germ-cell: BEP chemotherapy with >90% cure.
Any stage
Are there clinical trials I could join, for example of Raludotatug deruxtecan, Puxitatug samrotecan, PARP PET, Galleri?
Why: Trials are how the next standard of care is set; asking early keeps options open.
Would a second opinion at a high-volume centre change anything, and can you help arrange it?
Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Why: Supportive care improves quality of life and helps patients complete treatment.
I read that “No effective screening”. How does that affect my plan?
Why: Open problems are where trials and second opinions matter most.
I read that “PARP resistance via BRCA reversion”. How does that affect my plan?
Why: Open problems are where trials and second opinions matter most.